Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

E Solary

Showing results (151-160 of 170) with videos related to

Pageof 17
Sort By:
Oncogene|September 15, 2015
The HSP90 inhibitor, 17AAG, protects the intestinal stem cell niche and inhibits graft versus host disease developmentA-L Joly, A Deepti, A Seignez, et al.
Oncogene|June 3, 2016
The HSP90 inhibitor, 17AAG, protects the intestinal stem cell niche and inhibits graft versus host disease developmentA-L Joly, A Deepti, A Seignez, et al.
Leukemia|October 24, 2013
Use of the 46/1 haplotype to model JAK2(V617F) clonal architecture in PV patients: clonal evolution and impact of IFNα treatmentS Hasan, B Cassinat, N Droin, et al.
Blood|August 15, 1996
Combination of quinine as a potential reversing agent with mitoxantrone and cytarabine for the treatment of acute leukemias: a randomized multicenter studyE Solary, B Witz, D Caillot, et al.
Cell Death & Disease|July 27, 2013
Thrombocytopenia induced by the histone deacetylase inhibitor abexinostat involves p53-dependent and -independent mechanismsA Ali, O Bluteau, K Messaoudi, et al.
Leukemia|February 28, 2013
SETBP1 mutations in 658 patients with myelodysplastic syndromes, chronic myelomonocytic leukemia and secondary acute myeloid leukemiasF Damm, R Itzykson, O Kosmider, et al.
Leukemia Research|January 30, 2017
Use of 5-azacitidine for therapy-related myeloid neoplasms in patients with concomitant active neoplastic diseaseM Annereau, C Willekens, L El Halabi, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|February 16, 2000
Granulocyte colony-stimulating factor after intensive consolidation chemotherapy in acute myeloid leukemia: results of a randomized trial of the Groupe Ouest-Est Leucémies Aigues MyeloblastiquesJ L Harousseau, B Witz, B Lioure, et al.
Leukemia & Lymphoma|March 28, 1998
PreB1 (CD10-) acute lymphoblastic leukemia: immunophenotypic and genomic characteristics, clinical features and outcome in 38 adults and 26 children. The Groupe dEtude Immunologique des LeucémiesB Lenormand, M C Béné, J F Lesesve, et al.
Cell Death & Disease|October 5, 2012
CXCR4 inhibitors selectively eliminate CXCR4-expressing human acute myeloid leukemia cells in NOG mouse modelY Zhang, S Patel, H Abdelouahab, et al.
Pageof 17

Showing results (151-160 of 170) with videos related to

Sort By:
Pageof 17
Oncogene|September 15, 2015
The HSP90 inhibitor, 17AAG, protects the intestinal stem cell niche and inhibits graft versus host disease developmentA-L Joly, A Deepti, A Seignez, et al.
Oncogene|June 3, 2016
The HSP90 inhibitor, 17AAG, protects the intestinal stem cell niche and inhibits graft versus host disease developmentA-L Joly, A Deepti, A Seignez, et al.
Leukemia|October 24, 2013
Use of the 46/1 haplotype to model JAK2(V617F) clonal architecture in PV patients: clonal evolution and impact of IFNα treatmentS Hasan, B Cassinat, N Droin, et al.
Blood|August 15, 1996
Combination of quinine as a potential reversing agent with mitoxantrone and cytarabine for the treatment of acute leukemias: a randomized multicenter studyE Solary, B Witz, D Caillot, et al.
Cell Death & Disease|July 27, 2013
Thrombocytopenia induced by the histone deacetylase inhibitor abexinostat involves p53-dependent and -independent mechanismsA Ali, O Bluteau, K Messaoudi, et al.
Leukemia|February 28, 2013
SETBP1 mutations in 658 patients with myelodysplastic syndromes, chronic myelomonocytic leukemia and secondary acute myeloid leukemiasF Damm, R Itzykson, O Kosmider, et al.
Leukemia Research|January 30, 2017
Use of 5-azacitidine for therapy-related myeloid neoplasms in patients with concomitant active neoplastic diseaseM Annereau, C Willekens, L El Halabi, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|February 16, 2000
Granulocyte colony-stimulating factor after intensive consolidation chemotherapy in acute myeloid leukemia: results of a randomized trial of the Groupe Ouest-Est Leucémies Aigues MyeloblastiquesJ L Harousseau, B Witz, B Lioure, et al.
Leukemia & Lymphoma|March 28, 1998
PreB1 (CD10-) acute lymphoblastic leukemia: immunophenotypic and genomic characteristics, clinical features and outcome in 38 adults and 26 children. The Groupe dEtude Immunologique des LeucémiesB Lenormand, M C Béné, J F Lesesve, et al.
Cell Death & Disease|October 5, 2012
CXCR4 inhibitors selectively eliminate CXCR4-expressing human acute myeloid leukemia cells in NOG mouse modelY Zhang, S Patel, H Abdelouahab, et al.
Pageof 17